Cargando…

The TOMM40 ‘523’ polymorphism in disease risk and age of symptom onset in two independent cohorts of Parkinson’s disease

Abnormal mitochondrial function is a key process in the pathogenesis of Parkinson’s disease (PD). The central pore-forming protein TOM40 of the mitochondria is encoded by the translocase of outer mitochondrial membrane 40 homologue gene (TOMM40). The highly variant ‘523’ poly-T repeat is associated...

Descripción completa

Detalles Bibliográficos
Autores principales: Bakeberg, Megan C., Hoes, Madison E., Gorecki, Anastazja M., Theunissen, Frances, Pfaff, Abigail L., Kenna, Jade E., Plunkett, Kai, Kõks, Sulev, Akkari, P. Anthony, Mastaglia, Frank L., Anderton, Ryan S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973542/
https://www.ncbi.nlm.nih.gov/pubmed/33737565
http://dx.doi.org/10.1038/s41598-021-85510-0
_version_ 1783666863216001024
author Bakeberg, Megan C.
Hoes, Madison E.
Gorecki, Anastazja M.
Theunissen, Frances
Pfaff, Abigail L.
Kenna, Jade E.
Plunkett, Kai
Kõks, Sulev
Akkari, P. Anthony
Mastaglia, Frank L.
Anderton, Ryan S.
author_facet Bakeberg, Megan C.
Hoes, Madison E.
Gorecki, Anastazja M.
Theunissen, Frances
Pfaff, Abigail L.
Kenna, Jade E.
Plunkett, Kai
Kõks, Sulev
Akkari, P. Anthony
Mastaglia, Frank L.
Anderton, Ryan S.
author_sort Bakeberg, Megan C.
collection PubMed
description Abnormal mitochondrial function is a key process in the pathogenesis of Parkinson’s disease (PD). The central pore-forming protein TOM40 of the mitochondria is encoded by the translocase of outer mitochondrial membrane 40 homologue gene (TOMM40). The highly variant ‘523’ poly-T repeat is associated with age-related cognitive decline and age of onset in Alzheimer’s disease, but whether it plays a role in modifying the risk or clinical course of PD it yet to be elucidated. The TOMM40 ‘523’ allele length was determined in 634 people with PD and 422 healthy controls from an Australian cohort and the Parkinson’s Progression Markers Initiative (PPMI) cohort, using polymerase chain reaction or whole genome sequencing analysis. Genotype and allele frequencies of TOMM40 ‘523’ and APOE ε did not differ significantly between the cohorts. Analyses revealed TOMM40 ‘523’ allele groups were not associated with disease risk, while considering APOE ε genotype. Regression analyses revealed the TOMM40 S/S genotype was associated with a significantly later age of symptom onset in the PPMI PD cohort, but not after correction for covariates, or in the Australian cohort. Whilst variation in the TOMM40 ‘523’ polymorphism was not associated with PD risk, the possibility that it may be a modifying factor for age of symptom onset warrants further investigation in other PD populations.
format Online
Article
Text
id pubmed-7973542
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-79735422021-03-19 The TOMM40 ‘523’ polymorphism in disease risk and age of symptom onset in two independent cohorts of Parkinson’s disease Bakeberg, Megan C. Hoes, Madison E. Gorecki, Anastazja M. Theunissen, Frances Pfaff, Abigail L. Kenna, Jade E. Plunkett, Kai Kõks, Sulev Akkari, P. Anthony Mastaglia, Frank L. Anderton, Ryan S. Sci Rep Article Abnormal mitochondrial function is a key process in the pathogenesis of Parkinson’s disease (PD). The central pore-forming protein TOM40 of the mitochondria is encoded by the translocase of outer mitochondrial membrane 40 homologue gene (TOMM40). The highly variant ‘523’ poly-T repeat is associated with age-related cognitive decline and age of onset in Alzheimer’s disease, but whether it plays a role in modifying the risk or clinical course of PD it yet to be elucidated. The TOMM40 ‘523’ allele length was determined in 634 people with PD and 422 healthy controls from an Australian cohort and the Parkinson’s Progression Markers Initiative (PPMI) cohort, using polymerase chain reaction or whole genome sequencing analysis. Genotype and allele frequencies of TOMM40 ‘523’ and APOE ε did not differ significantly between the cohorts. Analyses revealed TOMM40 ‘523’ allele groups were not associated with disease risk, while considering APOE ε genotype. Regression analyses revealed the TOMM40 S/S genotype was associated with a significantly later age of symptom onset in the PPMI PD cohort, but not after correction for covariates, or in the Australian cohort. Whilst variation in the TOMM40 ‘523’ polymorphism was not associated with PD risk, the possibility that it may be a modifying factor for age of symptom onset warrants further investigation in other PD populations. Nature Publishing Group UK 2021-03-18 /pmc/articles/PMC7973542/ /pubmed/33737565 http://dx.doi.org/10.1038/s41598-021-85510-0 Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Bakeberg, Megan C.
Hoes, Madison E.
Gorecki, Anastazja M.
Theunissen, Frances
Pfaff, Abigail L.
Kenna, Jade E.
Plunkett, Kai
Kõks, Sulev
Akkari, P. Anthony
Mastaglia, Frank L.
Anderton, Ryan S.
The TOMM40 ‘523’ polymorphism in disease risk and age of symptom onset in two independent cohorts of Parkinson’s disease
title The TOMM40 ‘523’ polymorphism in disease risk and age of symptom onset in two independent cohorts of Parkinson’s disease
title_full The TOMM40 ‘523’ polymorphism in disease risk and age of symptom onset in two independent cohorts of Parkinson’s disease
title_fullStr The TOMM40 ‘523’ polymorphism in disease risk and age of symptom onset in two independent cohorts of Parkinson’s disease
title_full_unstemmed The TOMM40 ‘523’ polymorphism in disease risk and age of symptom onset in two independent cohorts of Parkinson’s disease
title_short The TOMM40 ‘523’ polymorphism in disease risk and age of symptom onset in two independent cohorts of Parkinson’s disease
title_sort tomm40 ‘523’ polymorphism in disease risk and age of symptom onset in two independent cohorts of parkinson’s disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973542/
https://www.ncbi.nlm.nih.gov/pubmed/33737565
http://dx.doi.org/10.1038/s41598-021-85510-0
work_keys_str_mv AT bakebergmeganc thetomm40523polymorphismindiseaseriskandageofsymptomonsetintwoindependentcohortsofparkinsonsdisease
AT hoesmadisone thetomm40523polymorphismindiseaseriskandageofsymptomonsetintwoindependentcohortsofparkinsonsdisease
AT goreckianastazjam thetomm40523polymorphismindiseaseriskandageofsymptomonsetintwoindependentcohortsofparkinsonsdisease
AT theunissenfrances thetomm40523polymorphismindiseaseriskandageofsymptomonsetintwoindependentcohortsofparkinsonsdisease
AT pfaffabigaill thetomm40523polymorphismindiseaseriskandageofsymptomonsetintwoindependentcohortsofparkinsonsdisease
AT kennajadee thetomm40523polymorphismindiseaseriskandageofsymptomonsetintwoindependentcohortsofparkinsonsdisease
AT plunkettkai thetomm40523polymorphismindiseaseriskandageofsymptomonsetintwoindependentcohortsofparkinsonsdisease
AT kokssulev thetomm40523polymorphismindiseaseriskandageofsymptomonsetintwoindependentcohortsofparkinsonsdisease
AT akkaripanthony thetomm40523polymorphismindiseaseriskandageofsymptomonsetintwoindependentcohortsofparkinsonsdisease
AT mastagliafrankl thetomm40523polymorphismindiseaseriskandageofsymptomonsetintwoindependentcohortsofparkinsonsdisease
AT andertonryans thetomm40523polymorphismindiseaseriskandageofsymptomonsetintwoindependentcohortsofparkinsonsdisease
AT bakebergmeganc tomm40523polymorphismindiseaseriskandageofsymptomonsetintwoindependentcohortsofparkinsonsdisease
AT hoesmadisone tomm40523polymorphismindiseaseriskandageofsymptomonsetintwoindependentcohortsofparkinsonsdisease
AT goreckianastazjam tomm40523polymorphismindiseaseriskandageofsymptomonsetintwoindependentcohortsofparkinsonsdisease
AT theunissenfrances tomm40523polymorphismindiseaseriskandageofsymptomonsetintwoindependentcohortsofparkinsonsdisease
AT pfaffabigaill tomm40523polymorphismindiseaseriskandageofsymptomonsetintwoindependentcohortsofparkinsonsdisease
AT kennajadee tomm40523polymorphismindiseaseriskandageofsymptomonsetintwoindependentcohortsofparkinsonsdisease
AT plunkettkai tomm40523polymorphismindiseaseriskandageofsymptomonsetintwoindependentcohortsofparkinsonsdisease
AT kokssulev tomm40523polymorphismindiseaseriskandageofsymptomonsetintwoindependentcohortsofparkinsonsdisease
AT akkaripanthony tomm40523polymorphismindiseaseriskandageofsymptomonsetintwoindependentcohortsofparkinsonsdisease
AT mastagliafrankl tomm40523polymorphismindiseaseriskandageofsymptomonsetintwoindependentcohortsofparkinsonsdisease
AT andertonryans tomm40523polymorphismindiseaseriskandageofsymptomonsetintwoindependentcohortsofparkinsonsdisease